Company Filing History:
2 out of 155 
2 out of 63 
Years Active: 2018-2019
Title: Lea Schroeder: Innovator in Cancer Therapy
Introduction
Lea Schroeder is a prominent inventor based in Heidelberg, Germany. She has made significant contributions to the field of cancer therapy, particularly through her innovative research involving parvoviruses and BCL-2 inhibitors. With a total of 2 patents, her work is paving the way for new treatment options for cancer patients.
Latest Patents
Lea Schroeder's latest patents focus on a pharmaceutical composition that combines a parvovirus with a BCL-2 inhibitor. This composition is designed for the treatment of cancer, specifically targeting solid tumors. The preferred inhibitors in her research are the BH3 mimetics ABT-737 and ABT-199. These advancements represent a promising approach to enhancing cancer therapy and improving patient outcomes.
Career Highlights
Throughout her career, Lea has worked with esteemed institutions such as the Deutsches Krebsforschungszentrum and Ruprecht-Karls-Universität Heidelberg. Her dedication to cancer research has established her as a key figure in the scientific community, contributing to the understanding and treatment of this complex disease.
Collaborations
Lea has collaborated with notable colleagues, including Antonio Marchini and Junwei Li. These partnerships have further enriched her research and expanded the impact of her work in the field of oncology.
Conclusion
Lea Schroeder's innovative contributions to cancer therapy highlight her role as a leading inventor in the medical field. Her research continues to inspire advancements in treatment options for cancer patients, showcasing the importance of innovation in healthcare.